The healthcare technology sector in 2026 has entered a structurally distinct phase of maturation, transitioning from the speculative, "growth-at-all-costs" venture capital paradigms of the early 2020s into a disciplined era defined by profitable efficiency, clinical validation and platform scale. Following several years of valuation corrections and capital constraints, global healthtech mergers and acquisitions (M&A) are accelerating rapidly. This resurgence is fueled by a ma